[1]
Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res., 1965, 37, 614-636.
[2]
Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res., 1961, 25, 585-621.
[3]
Chang, B.D.; Broude, E.V.; Dokmanovic, M.; Zhu, H.; Ruth, A.; Xuan, Y.; Kandel, E.S.; Lausch, E.; Christov, K.; Roninson, I.B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res., 1999, 59(15), 3761-3767.
[4]
te Poele, R.H.; Okorokov, A.L.; Jardine, L.; Cummings, J.; Joel, S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res., 2002, 62(4), 1876-1883.
[5]
Roberson, R.S.; Kussick, S.J.; Vallieres, E.; Chen, S.Y.; Wu, D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res., 2005, 65(7), 2795-2803.
[6]
Schmitt, C.A.; Fridman, J.S.; Yang, M.; Lee, S.; Baranov, E.; Hoffman, R.M.; Lowe, S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell, 2002, 109(3), 335-346.
[7]
Prieur, A.; Besnard, E.; Babled, A.; Lemaitre, J.M. p53 and p16(INK4A) independent induction of senescence by chromatin-dependent alteration of S-phase progression. Nat. Commun., 2011, 2, 473.
[8]
Tu, Z.; Aird, K.M.; Zhang, R. Chromatin remodeling, BRCA1, SAHF and cellular senescence. Cell Cycle, 2013, 12(11), 1653-1654.
[9]
Tu, Z.; Zhuang, X.; Yao, Y.G.; Zhang, R. BRG1 is required for formation of senescence-associated heterochromatin foci induced by oncogenic RAS or BRCA1 loss. Mol. Cell. Biol., 2013, 33(9), 1819-1829.
[10]
Krtolica, A.; Parrinello, S.; Lockett, S.; Desprez, P.Y.; Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA, 2001, 98(21), 12072-12077.
[11]
Parrinello, S.; Coppe, J.P.; Krtolica, A.; Campisi, J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci., 2005, 118(Pt 3), 485-496.
[12]
Zhang, Y.; Gao, Y.; Zhao, L.; Han, L.; Lu, Y.; Hou, P.; Shi, X.; Liu, X.; Tian, B.; Wang, X.; Huang, B.; Lu, J. Mitogen-activated protein kinase p38 and retinoblastoma protein signalling is required for DNA damage-mediated formation of senescence-associated heterochromatic foci in tumour cells. FEBS J., 2013, 280(18), 4625-4639.
[13]
Campisi, J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell, 2005, 120(4), 513-522.
[14]
Coppe, J.P.; Desprez, P.Y.; Krtolica, A.; Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol., 2010, 5, 99-118.
[15]
Bavik, C.; Coleman, I.; Dean, J.P.; Knudsen, B.; Plymate, S.; Nelson, P.S. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res., 2006, 66(2), 794-802.
[16]
Frey, A.B. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest., 2006, 116(10), 2587-2590.
[17]
Chen, P.; Guo, H.; Chen, J.; Fu, Y. The chemotherapeutic drug boanmycin induces cell senescence and senescence-associated secretory phenotype factors, thus acquiring the potential to remodel the tumor microenvironment. Anticancer Drugs, 2016, 27(2), 84-88.
[18]
Bringold, F.; Serrano, M. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol., 2000, 35(3), 317-329.
[19]
Lundberg, A.S.; Hahn, W.C.; Gupta, P.; Weinberg, R.A. Genes involved in senescence and immortalization. Curr. Opin. Cell Biol., 2000, 12(6), 705-709.
[20]
Dimauro, T.; David, G. Ras-induced senescence and its physiological relevance in cancer. Curr. Cancer Drug Targets, 2010, 10(8), 869-876.
[21]
Karnoub, A.E.; Weinberg, R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol., 2008, 9(7), 517-531.
[22]
Tu, Z.; Aird, K.M.; Bitler, B.G.; Nicodemus, J.P.; Beeharry, N.; Xia, B.; Yen, T.J.; Zhang, R. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev. Cell, 2011, 21(6), 1077-1091.
[23]
Tu, Z.; Aird, K.M.; Zhang, R. RAS, cellular senescence and transformation: the BRCA1 DNA repair pathway at the crossroads. Small GTPases, 2012, 3(3), 163-167.
[24]
Jacobs, J.J.; Keblusek, P.; Robanus-Maandag, E.; Kristel, P.; Lingbeek, M.; Nederlof, P.M.; van Welsem, T.; van de Vijver, M.J.; Koh, E.Y.; Daley, G.Q.; van Lohuizen, M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet., 2000, 26(3), 291-299.
[25]
Astle, M.V.; Hannan, K.M.; Ng, P.Y.; Lee, R.S.; George, A.J.; Hsu, A.K.; Haupt, Y.; Hannan, R.D.; Pearson, R.B. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene, 2012, 31(15), 1949-1962.
[26]
Pearson, M.; Carbone, R.; Sebastiani, C.; Cioce, M.; Fagioli, M.; Saito, S.; Higashimoto, Y.; Appella, E.; Minucci, S.; Pandolfi, P.P.; Pelicci, P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 2000, 406(6792), 207-210.
[27]
Ferbeyre, G.; de Stanchina, E.; Querido, E.; Baptiste, N.; Prives, C.; Lowe, S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev., 2000, 14(16), 2015-2027.
[28]
Boucher, M.J.; Jean, D.; Vezina, A.; Rivard, N. Dual role of MEK/ERK signaling in senescence and transformation of intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286(5), G736-G746.
[29]
Rayess, H.; Wang, M.B.; Srivatsan, E.S. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer, 2012, 130(8), 1715-1725.
[30]
Cordisco, S.; Maurelli, R.; Bondanza, S.; Stefanini, M.; Zambruno, G.; Guerra, L.; Dellambra, E. Bmi-1 reduction plays a key role in physiological and premature aging of primary human keratinocytes. J. Invest. Dermatol., 2010, 130(4), 1048-1062.
[31]
Sagata, N.; Watanabe, N.; Vande Woude, G.F.; Ikawa, Y. The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs. Nature, 1989, 342(6249), 512-518.
[32]
Shibuya, E.K.; Ruderman, J.V. Mos induces the in vitro activation of mitogen-activated protein kinases in lysates of frog oocytes and mammalian somatic cells. Mol. Biol. Cell, 1993, 4(8), 781-790.
[33]
Lin, A.W.; Barradas, M.; Stone, J.C.; van Aelst, L.; Serrano, M.; Lowe, S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev., 1998, 12(19), 3008-3019.
[34]
Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L.V.; Kolettas, E.; Niforou, K.; Zoumpourlis, V.C.; Takaoka, M.; Nakagawa, H.; Tort, F.; Fugger, K.; Johansson, F.; Sehested, M.; Andersen, C.L.; Dyrskjot, L.; Orntoft, T.; Lukas, J.; Kittas, C.; Helleday, T.; Halazonetis, T.D.; Bartek, J.; Gorgoulis, V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature, 2006, 444(7119), 633-637.
[35]
Fujita, N.; Sato, S.; Katayama, K.; Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem., 2002, 277(32), 28706-28713.
[36]
Chu, E.C.; Tarnawski, A.S. PTEN regulatory functions in tumor suppression and cell biology. Med. Sci. Monit., 2004, 10(10), RA235-RA241.
[37]
Mallette, F.A.; Gaumont-Leclerc, M.F.; Ferbeyre, G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev., 2007, 21(1), 43-48.
[38]
Basham, B.; Sathe, M.; Grein, J.; McClanahan, T.; D’Andrea, A.; Lees, E.; Rascle, A. In vivo identification of novel STAT5 target genes. Nucleic Acids Res., 2008, 36(11), 3802-3818.
[39]
Mallette, F.A.; Moiseeva, O.; Calabrese, V.; Mao, B.; Gaumont-Leclerc, M.F.; Ferbeyre, G. Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence. Ann. N. Y. Acad. Sci., 2010, 1197, 142-151.
[40]
Calabrese, V.; Mallette, F.A.; Deschenes-Simard, X.; Ramanathan, S.; Gagnon, J.; Moores, A.; Ilangumaran, S.; Ferbeyre, G. SOCS1 links cytokine signaling to p53 and senescence. Mol. Cell, 2009, 36(5), 754-767.
[41]
Ferbeyre, G.; Moriggl, R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim. Biophys. Acta, 2011, 1815(1), 104-114.
[42]
Basu, D.; Reyes-Mugica, M.; Rebbaa, A. Role of the beta catenin destruction complex in mediating chemotherapy-induced senescence-associated secretory phenotype. PLoS One, 2012, 7(12), e52188.
[43]
Yu, S.; Wang, X.; Geng, P.; Tang, X.; Xiang, L.; Lu, X.; Li, J.; Ruan, Z.; Chen, J.; Xie, G.; Wang, Z.; Ou, J.; Peng, Y.; Luo, X.; Zhang, X.; Dong, Y.; Pang, X.; Miao, H.; Chen, H.; Liang, H. Melatonin regulates PARP1 to control the senescence-associated secretory phenotype (SASP) in human fetal lung fibroblast cells. J. Pineal Res., 2017, 63(1)
[44]
Moiseeva, O.; Deschenes-Simard, X.; St-Germain, E.; Igelmann, S.; Huot, G.; Cadar, A.E.; Bourdeau, V.; Pollak, M.N.; Ferbeyre, G. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell, 2013, 12(3), 489-498.
[45]
Macia, A.; Vaquero, M.; Gou-Fabregas, M.; Castelblanco, E.; Valdivielso, J.M.; Anerillas, C.; Mauricio, D.; Matias-Guiu, X.; Ribera, J.; Encinas, M. Sprouty1 induces a senescence-associated secretory phenotype by regulating NFkappaB activity: implications for tumorigenesis. Cell Death Differ., 2014, 21(2), 333-343.
[46]
Coppe, J.P.; Patil, C.K.; Rodier, F.; Sun, Y.; Munoz, D.P.; Goldstein, J.; Nelson, P.S.; Desprez, P.Y.; Campisi, J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol., 2008, 6(12), 2853-2868.
[47]
Rodier, F.; Coppe, J.P.; Patil, C.K.; Hoeijmakers, W.A.; Munoz, D.P.; Raza, S.R.; Freund, A.; Campeau, E.; Davalos, A.R.; Campisi, J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol., 2009, 11(8), 973-979.
[48]
Mantovani, A.; Locati, M.; Vecchi, A.; Sozzani, S.; Allavena, P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol., 2001, 22(6), 328-336.
[49]
Wajapeyee, N.; Serra, R.W.; Zhu, X.; Mahalingam, M.; Green, M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell, 2008, 132(3), 363-374.
[50]
Huang, M.; Whang, P.; Lewicki, P.; Mitchell, B.S. Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53. Mol. Pharmacol., 2011, 80(1), 40-48.
[51]
Manfe, V.; Biskup, E.; Johansen, P.; Kamstrup, M.R.; Krejsgaard, T.F.; Morling, N.; Wulf, H.C.; Gniadecki, R. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. J. Invest. Dermatol., 2012, 132(5), 1487-1496.
[52]
Ling, X.; Xu, C.; Fan, C.; Zhong, K.; Li, F.; Wang, X. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Res., 2014, 74(24), 7487-7497.
[53]
Drosten, M.; Dhawahir, A.; Sum, E.Y.; Urosevic, J.; Lechuga, C.G.; Esteban, L.M.; Castellano, E.; Guerra, C.; Santos, E.; Barbacid, M. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J., 2010, 29(6), 1091-1104.
[54]
Miliani de Marval, P.L.; Macias, E.; Conti, C.J.; Rodriguez-Puebla, M.L. Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene, 2004, 23(10), 1863-1873.
[55]
Leontieva, O.V.; Blagosklonny, M.V. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle, 2013, 12(18), 3063-3069.
[56]
Leontieva, O.V.; Demidenko, Z.N.; Blagosklonny, M.V. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ., 2013, 20(9), 1241-1249.
[57]
Perez, M.; Munoz-Galvan, S.; Jimenez-Garcia, M.P.; Marin, J.J.; Carnero, A. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget, 2015, 6(38), 40557-40574.
[58]
Hu, W.; Sung, T.; Jessen, B.A.; Thibault, S.; Finkelstein, M.B.; Khan, N.K.; Sacaan, A.I. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin. Cancer Res., 2016, 22(8), 2000-2008.
[59]
Yoshida, A.; Lee, E.K.; Diehl, J.A. Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6. Cancer Res., 2016, 76(10), 2990-3002.
[60]
Rader, J.; Russell, M.R.; Hart, L.S.; Nakazawa, M.S.; Belcastro, L.T.; Martinez, D.; Li, Y.; Carpenter, E.L.; Attiyeh, E.F.; Diskin, S.J.; Kim, S.; Parasuraman, S.; Caponigro, G.; Schnepp, R.W.; Wood, A.C.; Pawel, B.; Cole, K.A.; Maris, J.M. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin. Cancer Res., 2013, 19(22), 6173-6182.
[61]
Park, J.Y.; Park, S.H.; Weiss, R.H. Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am. J. Nephrol., 2009, 29(6), 509-515.
[62]
Oliva, J.L.; Caino, M.C.; Senderowicz, A.M.; Kazanietz, M.G. S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells. J. Biol. Chem., 2008, 283(9), 5466-5476.
[63]
Mason, S.A.; Cozzi, S.J.; Pierce, C.J.; Pavey, S.J.; Parsons, P.G.; Boyle, G.M. The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest. New Drugs, 2010, 28(5), 575-586.
[64]
Cozzi, S.J.; Parsons, P.G.; Ogbourne, S.M.; Pedley, J.; Boyle, G.M. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res., 2006, 66(20), 10083-10091.
[65]
Marusyk, A.; Wheeler, L.J.; Mathews, C.K.; DeGregori, J. p53 mediates senescence-like arrest induced by chronic replicational stress. Mol. Cell. Biol., 2007, 27(15), 5336-5351.
[66]
Maya-Mendoza, A.; Merchut-Maya, J.M.; Bartkova, J.; Bartek, J.; Streuli, C.H.; Jackson, D.A. Immortalised breast epithelia survive prolonged DNA replication stress and return to cycle from a senescent-like state. Cell Death Dis., 2014, 5, e1351.
[67]
Michishita, E.; Nakabayashi, K.; Suzuki, T.; Kaul, S.C.; Ogino, H.; Fujii, M.; Mitsui, Y.; Ayusawa, D. 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J. Biochem., 1999, 126(6), 1052-1059.
[68]
Suzuki, T.; Minagawa, S.; Michishita, E.; Ogino, H.; Fujii, M.; Mitsui, Y.; Ayusawa, D. Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells. Exp. Gerontol., 2001, 36(3), 465-474.
[69]
Masterson, J.C.; O’Dea, S. 5-Bromo-2-deoxyuridine activates DNA damage signalling responses and induces a senescence-like phenotype in p16-null lung cancer cells. Anticancer Drugs, 2007, 18(9), 1053-1068.
[70]
Nair, R.R.; Bagheri, M.; Saini, D.K. Temporally distinct roles of ATM and ROS in genotoxic-stress-dependent induction and maintenance of cellular senescence. J. Cell Sci., 2015, 128(2), 342-353.
[71]
Yeo, E.J.; Hwang, Y.C.; Kang, C.M.; Kim, I.H.; Kim, D.I.; Parka, J.S.; Choy, H.E.; Park, W.Y.; Park, S.C. Senescence-like changes induced by hydroxyurea in human diploid fibroblasts. Exp. Gerontol., 2000, 35(5), 553-571.
[72]
Hong, S.H.; Hong, B.; Kim, D.C.; Rho, M.S.; Park, J.I.; Rha, S.H.; Jun, H.S.; Jeong, J.S. Involvement of mitogen-activated protein kinases and p21Waf1 in hydroxyurea-induced G1 arrest and senescence of McA-RH7777 rat hepatoma cell line. Exp. Mol. Med., 2004, 36(5), 493-498.
[73]
Park, J.I.; Jeong, J.S.; Han, J.Y.; Kim, D.I.; Gao, Y.H.; Park, S.C.; Rodgers, G.P.; Kim, I.H. Hydroxyurea induces a senescence-like change of K562 human erythroleukemia cell. J. Cancer Res. Clin. Oncol., 2000, 126(8), 455-460.
[74]
Modrak, D.E.; Leon, E.; Goldenberg, D.M.; Gold, D.V. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol. Cancer Res., 2009, 7(6), 890-896.
[75]
Sumikawa, E.; Matsumoto, Y.; Sakemura, R.; Fujii, M.; Ayusawa, D. Prolonged unbalanced growth induces cellular senescence markers linked with mechano transduction in normal and tumor cells. Biochem. Biophys. Res. Commun., 2005, 335(2), 558-565.
[76]
Kobayashi, Y.; Lee, S.S.; Arai, R.; Miki, K.; Fujii, M.; Ayusawa, D. ERK1/2 mediates unbalanced growth leading to senescence induced by excess thymidine in human cells. Biochem. Biophys. Res. Commun., 2012, 425(4), 897-901.
[77]
Robles, S.J.; Adami, G.R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene, 1998, 16(9), 1113-1123.
[78]
Minieri, V.; Saviozzi, S.; Gambarotta, G.; Lo Iacono, M.; Accomasso, L.; Cibrario Rocchietti, E.; Gallina, C.; Turinetto, V.; Giachino, C. Persistent DNA damage-induced premature senescence alters the functional features of human bone marrow mesenchymal stem cells. J. Cell. Mol. Med., 2015, 19(4), 734-743.
[79]
Mansilla, S.; Pina, B.; Portugal, J. Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. Biochem. J., 2003, 372(Pt 3), 703-711.
[80]
Chang, B.D.; Xuan, Y.; Broude, E.V.; Zhu, H.; Schott, B.; Fang, J.; Roninson, I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene, 1999, 18(34), 4808-4818.
[81]
Elmore, L.W.; Rehder, C.W.; Di, X.; McChesney, P.A.; Jackson-Cook, C.K.; Gewirtz, D.A.; Holt, S.E. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem., 2002, 277(38), 35509-35515.
[82]
Sliwinska, M.A.; Mosieniak, G.; Wolanin, K.; Babik, A.; Piwocka, K.; Magalska, A.; Szczepanowska, J.; Fronk, J.; Sikora, E. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech. Ageing Dev., 2009, 130(1-2), 24-32.
[83]
Spallarossa, P.; Altieri, P.; Aloi, C.; Garibaldi, S.; Barisione, C.; Ghigliotti, G.; Fugazza, G.; Barsotti, A.; Brunelli, C. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am. J. Physiol. Heart Circ. Physiol., 2009, 297(6), H2169-H2181.
[84]
Leontieva, O.V.; Gudkov, A.V.; Blagosklonny, M.V. Weak p53 permits senescence during cell cycle arrest. Cell Cycle, 2010, 9(21), 4323-4327.
[85]
Litwiniec, A.; Grzanka, A.; Helmin-Basa, A.; Gackowska, L.; Grzanka, D. Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. J. Cancer Res. Clin. Oncol., 2010, 136(5), 717-736.
[86]
Jackson, J.G.; Pant, V.; Li, Q.; Chang, L.L.; Quintas-Cardama, A.; Garza, D.; Tavana, O.; Yang, P.; Manshouri, T.; Li, Y.; El-Naggar, A.K.; Lozano, G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell, 2012, 21(6), 793-806.
[87]
Piegari, E.; De Angelis, A.; Cappetta, D.; Russo, R.; Esposito, G.; Costantino, S.; Graiani, G.; Frati, C.; Prezioso, L.; Berrino, L.; Urbanek, K.; Quaini, F.; Rossi, F. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res. Cardiol., 2013, 108(2), 334.
[88]
Park, C.; Lee, I.; Kang, W.K. E2F-1 is a critical modulator of cellular senescence in human cancer. Int. J. Mol. Med., 2006, 17(5), 715-720.
[89]
Zhao, H.; Halicka, H.D.; Traganos, F.; Jorgensen, E.; Darzynkiewicz, Z. New biomarkers probing depth of cell senescence assessed by laser scanning cytometry. Cytometry A, 2010, 77(11), 999-1007.
[90]
Probin, V.; Wang, Y.; Bai, A.; Zhou, D. Busulfan selectively induces cellular senescence but not apoptosis in WI38 fibroblasts via a p53-independent but extracellular signal-regulated kinase-p38 mitogen-activated protein kinase-dependent mechanism. J. Pharmacol. Exp. Ther., 2006, 319(2), 551-560.
[91]
Litwiniec, A.; Gackowska, L.; Helmin-Basa, A.; Zuryn, A.; Grzanka, A. Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin. Cancer Cell Int., 2013, 13(1), 9.
[92]
Velichko, A.K.; Petrova, N.V.; Razin, S.V.; Kantidze, O.L. Mechanism of heat stress-induced cellular senescence elucidates the exclusive vulnerability of early S-phase cells to mild genotoxic stress. Nucleic Acids Res., 2015, 43(13), 6309-6320.
[93]
Wang, X.; Wong, S.C.; Pan, J.; Tsao, S.W.; Fung, K.H.; Kwong, D.L.; Sham, J.S.; Nicholls, J.M. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res., 1998, 58(22), 5019-5022.
[94]
Berndtsson, M.; Hagg, M.; Panaretakis, T.; Havelka, A.M.; Shoshan, M.C.; Linder, S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer, 2007, 120(1), 175-180.
[95]
Qu, K.; Lin, T.; Wang, Z.; Liu, S.; Chang, H.; Xu, X.; Meng, F.; Zhou, L.; Wei, J.; Tai, M.; Dong, Y.; Liu, C. Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma. Front. Med., 2014, 8(2), 227-235.
[96]
Veena, M.S.; Wilken, R.; Zheng, J.Y.; Gholkar, A.; Venkatesan, N.; Vira, D.; Ahmed, S.; Basak, S.K.; Dalgard, C.L.; Ravichandran, S.; Batra, R.K.; Kasahara, N.; Elashoff, D.; Fishbein, M.C.; Whitelegge, J.P.; Torres, J.Z.; Wang, M.B.; Srivatsan, E.S. p16 Protein and gigaxonin are associated with the ubiquitination of NFkappaB in cisplatin-induced senescence of cancer cells. J. Biol. Chem., 2014, 289(50), 34921-34937.
[97]
McKenna, E.; Traganos, F.; Zhao, H.; Darzynkiewicz, Z. Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence. Cell Cycle, 2012, 11(16), 3132-3140.
[98]
Palaniyappan, A. Cyclophosphamide induces premature senescence in normal human fibroblasts by activating MAP kinases. Biogerontology, 2009, 10(6), 677-682.
[99]
Ewald, J.A.; Peters, N.; Desotelle, J.A.; Hoffmann, F.M.; Jarrard, D.F. A high-throughput method to identify novel senescence-inducing compounds. J. Biomol. Screen., 2009, 14(7), 853-858.
[100]
Hirose, Y.; Berger, M.S.; Pieper, R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res., 2001, 61(5), 1957-1963.
[101]
Mhaidat, N.M.; Zhang, X.D.; Allen, J.; Avery-Kiejda, K.A.; Scott, R.J.; Hersey, P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br. J. Cancer, 2007, 97(9), 1225-1233.
[102]
Chen, Q.; Ames, B.N. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc. Natl. Acad. Sci. USA, 1994, 91(10), 4130-4134.
[103]
Chen, Q.M.; Bartholomew, J.C.; Campisi, J.; Acosta, M.; Reagan, J.D.; Ames, B.N. Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication. Biochem. J., 1998, 332(Pt 1), 43-50.
[104]
Frippiat, C.; Dewelle, J.; Remacle, J.; Toussaint, O. Signal transduction in H2O2-induced senescence-like phenotype in human diploid fibroblasts. Free Radic. Biol. Med., 2002, 33(10), 1334-1346.
[105]
Yoshizaki, K.; Fujiki, T.; Tsunematsu, T.; Yamashita, M.; Udono, M.; Shirahata, S.; Katakura, Y. Pro-senescent effect of hydrogen peroxide on cancer cells and its possible application to tumor suppression. Biosci. Biotechnol. Biochem., 2009, 73(2), 311-315.
[106]
Ido, Y.; Duranton, A.; Lan, F.; Cacicedo, J.M.; Chen, T.C.; Breton, L.; Ruderman, N.B. Acute activation of AMP-activated protein kinase prevents H2O2-induced premature senescence in primary human keratinocytes. PLoS One, 2012, 7(4), e35092.
[107]
Suzuki, E.; Takahashi, M.; Oba, S.; Nishimatsu, H. Oncogene- and oxidative stress-induced cellular senescence shows distinct expression patterns of proinflammatory cytokines in vascular endothelial cells. Sci. World J., 2013, 2013, 754735.
[108]
Burova, E.; Borodkina, A.; Shatrova, A.; Nikolsky, N. Sublethal oxidative stress induces the premature senescence of human mesenchymal stem cells derived from endometrium. Oxid. Med. Cell. Longev., 2013, 2013, 474931.
[109]
Borodkina, A.; Shatrova, A.; Abushik, P.; Nikolsky, N.; Burova, E. Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. Aging (Albany N.Y.), 2014, 6(6), 481-495.
[110]
Gorbunova, V.; Seluanov, A.; Pereira-Smith, O.M. Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J. Biol. Chem., 2002, 277(41), 38540-38549.
[111]
Chretien, A.; Piront, N.; Delaive, E.; Demazy, C.; Ninane, N.; Toussaint, O. Increased abundance of cytoplasmic and nuclear caveolin 1 in human diploid fibroblasts in H(2)O(2)-induced premature senescence and interplay with p38alpha(MAPK). FEBS Lett., 2008, 582(12), 1685-1692.
[112]
Zdanov, S.; Debacq-Chainiaux, F.; Remacle, J.; Toussaint, O. Identification of p38MAPK-dependent genes with changed transcript abundance in H2O2-induced premature senescence of IMR-90 hTERT human fibroblasts. FEBS Lett., 2006, 580(27), 6455-6463.
[113]
Ota, H.; Eto, M.; Kano, M.R.; Ogawa, S.; Iijima, K.; Akishita, M.; Ouchi, Y. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2008, 28(9), 1634-1639.
[114]
von Zglinicki, T.; Pilger, R.; Sitte, N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic. Biol. Med., 2000, 28(1), 64-74.
[115]
Felipe, K.B.; Benites, J.; Glorieux, C.; Sid, B.; Valenzuela, M.; Kviecinski, M.R.; Pedrosa, R.C.; Valderrama, J.A.; Leveque, P.; Gallez, B.; Verrax, J.; Buc Calderon, P. Antiproliferative effects of phenylaminonaphthoquinones are increased by ascorbate and associated with the appearance of a senescent phenotype in human bladder cancer cells. Biochem. Biophys. Res. Commun., 2013, 433(4), 573-578.
[116]
Aoshiba, K.; Tsuji, T.; Nagai, A. Bleomycin induces cellular senescence in alveolar epithelial cells. Eur. Respir. J., 2003, 22(3), 436-443.
[117]
Linge, A.; Weinhold, K.; Blasche, R.; Kasper, M.; Barth, K. Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int. J. Biochem. Cell Biol., 2007, 39(10), 1964-1974.
[118]
Pazolli, E.; Alspach, E.; Milczarek, A.; Prior, J.; Piwnica-worms, D.; Stewart, S.A. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res., 2012, 72(9), 2251-2261.
[119]
Bearss, D.J.; Hurley, L.H.; Von Hoff, D.D. Telomere maintenance mechanisms as a target for drug development. Oncogene, 2000, 19(56), 6632-6641.
[120]
Multani, A.S.; Furlong, C.; Pathak, S. Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine. Int. J. Oncol., 1998, 13(5), 923-925.
[121]
Demir, M.; Laywell, E.D. Neurotoxic effects of AZT on developing and adult neurogenesis. Front. Neurosci., 2015, 9, 93.
[122]
Datta, A.; Bellon, M.; Sinha-Datta, U.; Bazarbachi, A.; Lepelletier, Y.; Canioni, D.; Waldmann, T.A.; Hermine, O.; Nicot, C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood, 2006, 108(3), 1021-1029.
[123]
Zhou, J.M.; Zhu, X.F.; Lu, Y.J.; Deng, R.; Huang, Z.S.; Mei, Y.P.; Wang, Y.; Huang, W.L.; Liu, Z.C.; Gu, L.Q.; Zeng, Y.X. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25(4), 503-511.
[124]
Huang, F.C.; Chang, C.C.; Wang, J.M.; Chang, T.C.; Lin, J.J. Induction of senescence in cancer cells by the G-quadruplex stabilizer, BMVC4, is independent of its telomerase inhibitory activity. Br. J. Pharmacol., 2012, 167(2), 393-406.
[125]
Muller, S.; Sanders, D.A.; Di Antonio, M.; Matsis, S.; Riou, J.F.; Rodriguez, R.; Balasubramanian, S. Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells. Org. Biomol. Chem., 2012, 10(32), 6537-6546.
[126]
Riou, J.F.; Guittat, L.; Mailliet, P.; Laoui, A.; Renou, E.; Petitgenet, O.; Megnin-Chanet, F.; Helene, C.; Mergny, J.L. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. USA, 2002, 99(5), 2672-2677.
[127]
Taka, T.; Huang, L.; Wongnoppavich, A.; Tam-Chang, S.W.; Lee, T.R.; Tuntiwechapikul, W. Telomere shortening and cell senescence induced by perylene derivatives in A549 human lung cancer cells. Bioorg. Med. Chem., 2013, 21(4), 883-890.
[128]
Zhao, L.; Wink, M. The beta-carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by down-regulating hTERT mRNA expression accompanied by an accelerated senescent phenotype. PeerJ, 2013, 1, e174.
[129]
Marconett, C.N.; Sundar, S.N.; Tseng, M.; Tin, A.S.; Tran, K.Q.; Mahuron, K.M.; Bjeldanes, L.F.; Firestone, G.L. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis, 2011, 32(9), 1315-1323.
[130]
Shimizu, H.; Bolati, D.; Adijiang, A.; Muteliefu, G.; Enomoto, A.; Nishijima, F.; Dateki, M.; Niwa, T. NF-kappaB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells. Am. J. Physiol. Cell Physiol., 2011, 301(5), C1201-C1212.
[131]
Shimizu, H.; Bolati, D.; Adijiang, A.; Enomoto, A.; Nishijima, F.; Dateki, M.; Niwa, T. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am. J. Physiol. Cell Physiol., 2010, 299(5), C1110-C1117.
[132]
Damm, K.; Hemmann, U.; Garin-Chesa, P.; Hauel, N.; Kauffmann, I.; Priepke, H.; Niestroj, C.; Daiber, C.; Enenkel, B.; Guilliard, B.; Lauritsch, I.; Muller, E.; Pascolo, E.; Sauter, G.; Pantic, M.; Martens, U.M.; Wenz, C.; Lingner, J.; Kraut, N.; Rettig, W.J.; Schnapp, A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 2001, 20(24), 6958-6968.
[133]
Yokoyama, Y.; Takahashi, Y.; Shinohara, A.; Wan, X.; Takahashi, S.; Niwa, K.; Tamaya, T. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun., 2000, 273(1), 316-321.
[134]
Denchi, E.L.; de Lange, T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature, 2007, 448(7157), 1068-1071.
[135]
Vogt, M.; Haggblom, C.; Yeargin, J.; Christiansen-Weber, T.; Haas, M. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Differ., 1998, 9(2), 139-146.
[136]
Venturelli, S.; Berger, A.; Weiland, T.; Essmann, F.; Waibel, M.; Nuebling, T.; Hacker, S.; Schenk, M.; Schulze-Osthoff, K.; Salih, H.R.; Fulda, S.; Sipos, B.; Johnstone, R.W.; Lauer, U.M.; Bitzer, M. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumor cells. Mol. Cancer Ther., 2013, 12(10), 2226-2236.
[137]
Widodo, N.; Deocaris, C.C.; Kaur, K.; Hasan, K.; Yaguchi, T.; Yamasaki, K.; Sugihara, T.; Ishii, T.; Wadhwa, R.; Kaul, S.C. Stress chaperones, mortalin, and pex19p mediate 5-aza-2′ deoxycytidine-induced senescence of cancer cells by DNA methylation-independent pathway. J. Gerontol. A Biol. Sci. Med. Sci., 2007, 62(3), 246-255.
[138]
Amatori, S.; Bagaloni, I.; Viti, D.; Fanelli, M. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma. Lung Cancer, 2011, 71(1), 113-115.
[139]
Yuan, Y.; Wang, Q.; Paulk, J.; Kubicek, S.; Kemp, M.M.; Adams, D.J.; Shamji, A.F.; Wagner, B.K.; Schreiber, S.L. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem. Biol., 2012, 7(7), 1152-1157.
[140]
Ogryzko, V.V.; Hirai, T.H.; Russanova, V.R.; Barbie, D.A.; Howard, B.H. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol. Cell. Biol., 1996, 16(9), 5210-5218.
[141]
Xiao, H.; Hasegawa, T.; Miyaishi, O.; Ohkusu, K.; Isobe, K. Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner. Biochem. Biophys. Res. Commun., 1997, 237(2), 457-460.
[142]
Terao, Y.; Nishida, J.; Horiuchi, S.; Rong, F.; Ueoka, Y.; Matsuda, T.; Kato, H.; Furugen, Y.; Yoshida, K.; Kato, K.; Wake, N. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer, 2001, 94(2), 257-267.
[143]
Place, R.F.; Noonan, E.J.; Giardina, C. HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol., 2005, 6, 37.
[144]
Abramova, M.V.; Pospelova, T.V.; Nikulenkov, F.P.; Hollander, C.M.; Fornace, A.J. Jr.; Pospelov, V.A. G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin. J. Biol. Chem., 2006, 281(30), 21040-21051.
[145]
Pospelova, T.V.; Demidenko, Z.N.; Bukreeva, E.I.; Pospelov, V.A.; Gudkov, A.V.; Blagosklonny, M.V. Pseudo-DNA damage response in senescent cells. Cell Cycle, 2009, 8(24), 4112-4118.
[146]
Xu, W.S.; Perez, G.; Ngo, L.; Gui, C.Y.; Marks, P.A. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res., 2005, 65(17), 7832-7839.
[147]
Cain, J.E.; McCaw, A.; Jayasekara, W.S.; Rossello, F.J.; Marini, K.D.; Irving, A.T.; Kansara, M.; Thomas, D.M.; Ashley, D.M.; Watkins, D.N. Sustained low-dose treatment with the histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells. Sarcoma, 2013, 2013, 608964.
[148]
Kim, H.D.; Jang, C.Y.; Choe, J.M.; Sohn, J.; Kim, J. Phenylbutyric acid induces the cellular senescence through an Akt/p21(WAF1) signaling pathway. Biochem. Biophys. Res. Commun., 2012, 422(2), 213-218.
[149]
Li, X.N.; Shu, Q.; Su, J.M.; Perlaky, L.; Blaney, S.M.; Lau, C.C. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther., 2005, 4(12), 1912-1922.
[150]
An, H.M.; Xue, Y.F.; Shen, Y.L.; Du, Q.; Hu, B. Sodium valproate induces cell senescence in human hepatocarcinoma cells. Molecules, 2013, 18(12), 14935-14947.
[151]
Di Bernardo, G.; Squillaro, T.; Dell’Aversana, C.; Miceli, M.; Cipollaro, M.; Cascino, A.; Altucci, L.; Galderisi, U. Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev., 2009, 18(4), 573-581.
[152]
Mosieniak, G.; Adamowicz, M.; Alster, O.; Jaskowiak, H.; Szczepankiewicz, A.A.; Wilczynski, G.M.; Ciechomska, I.A.; Sikora, E. Curcumin induces permanent growth arrest of human colon cancer cells: link between senescence and autophagy. Mech. Ageing Dev., 2012, 133(6), 444-455.
[153]
Hendrayani, S.F.; Al-Khalaf, H.H.; Aboussekhra, A. Curcumin triggers p16-dependent senescence in active breast cancer-associated fibroblasts and suppresses their paracrine procarcinogenic effects. Neoplasia, 2013, 15(6), 631-640.
[154]
Grabowska, W.; Kucharewicz, K.; Wnuk, M.; Lewinska, A.; Suszek, M.; Przybylska, D.; Mosieniak, G.; Sikora, E.; Bielak-Zmijewska, A. Curcumin induces senescence of primary human cells building the vasculature in a DNA damage and ATM-independent manner. Age (Dordr.), 2015, 37(1), 9744.
[155]
Gewirtz, D.A.; Holt, S.E.; Elmore, L.W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem. Pharmacol., 2008, 76(8), 947-957.
[156]
Klein, L.E.; Freeze, B.S.; Smith, A.B. 3rd.; Horwitz, S.B. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle, 2005, 4(3), 501-507.
[157]
Arthur, C.R.; Gupton, J.T.; Kellogg, G.E.; Yeudall, W.A.; Cabot, M.C.; Newsham, I.F.; Gewirtz, D.A. Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison. Biochem. Pharmacol., 2007, 74(7), 981-991.
[158]
Tierno, M.B.; Kitchens, C.A.; Petrik, B.; Graham, T.H.; Wipf, P.; Xu, F.L.; Saunders, W.S.; Raccor, B.S.; Balachandran, R.; Day, B.W.; Stout, J.R.; Walczak, C.E.; Ducruet, A.P.; Reese, C.E.; Lazo, J.S. Microtubule binding and disruption and induction of premature senescence by disorazole C(1). J. Pharmacol. Exp. Ther., 2009, 328(3), 715-722.
[159]
Chan, A.; Gilfillan, C.; Templeton, N.; Paterson, I.; Northcote, P.T.; Miller, J.H. Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A. Invest. New Drugs, 2017, 35(6), 706-717.
[160]
Chao, S.K.; Lin, J.; Brouwer-Visser, J.; Smith, A.B., III; Horwitz, S.B.; McDaid, H.M. Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent. Proc. Natl. Acad. Sci. USA, 2011, 108(1), 391-396.
[161]
Duan, L.; Sterba, K.; Kolomeichuk, S.; Kim, H.; Brown, P.H.; Chambers, T.C. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem. Pharmacol., 2007, 73(4), 481-490.
[162]
Volpp, K.G.; John, L.K.; Troxel, A.B.; Norton, L.; Fassbender, J.; Loewenstein, G. Financial incentive-based approaches for weight loss: a randomized trial. JAMA, 2008, 300(22), 2631-2637.
[163]
Campisi, J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev., 2011, 21(1), 107-112.
[164]
Laberge, R.M.; Zhou, L.; Sarantos, M.R.; Rodier, F.; Freund, A.; de Keizer, P.L.; Liu, S.; Demaria, M.; Cong, Y.S.; Kapahi, P.; Desprez, P.Y.; Hughes, R.E.; Campisi, J. Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell, 2012, 11(4), 569-578.
[165]
Lim, H.; Park, H.; Kim, H.P. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts. Biochem. Pharmacol., 2015, 96(4), 337-348.
[166]
Braig, M.; Lee, S.; Loddenkemper, C.; Rudolph, C.; Peters, A.H.; Schlegelberger, B.; Stein, H.; Dorken, B.; Jenuwein, T.; Schmitt, C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 2005, 436(7051), 660-665.
[167]
Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol., 2013, 75, 685-705.
[168]
Chien, Y.; Scuoppo, C.; Wang, X.; Fang, X.; Balgley, B.; Bolden, J.E.; Premsrirut, P.; Luo, W.; Chicas, A.; Lee, C.S.; Kogan, S.C.; Lowe, S.W. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev., 2011, 25(20), 2125-2136.
[169]
Quesnel, B. Tumor dormancy and immunoescape. APMIS, 2008, 116(7-8), 685-694.
[170]
Giancotti, F.G. Mechanisms governing metastatic dormancy and reactivation. Cell, 2013, 155(4), 750-764.
[171]
Milanovic, M.; Fan, D.N.Y.; Belenki, D.; Dabritz, J.H.M.; Zhao, Z.; Yu, Y.; Dorr, J.R.; Dimitrova, L.; Lenze, D.; Monteiro Barbosa, I.A.; Mendoza-Parra, M.A.; Kanashova, T.; Metzner, M.; Pardon, K.; Reimann, M.; Trumpp, A.; Dorken, B.; Zuber, J.; Gronemeyer, H.; Hummel, M.; Dittmar, G.; Lee, S.; Schmitt, C.A. Senescence-associated reprogramming promotes cancer stemness. Nature, 2018, 553(7686), 96.
